Kenneth J. Valenzano

Author

Amicus Therapeutics (United States)

Also Known As

K Valenzano, K. J. Valenzano, K.J. Valenzano, Kenneth J Valenzano, Kenneth J. Valenzano, Kenneth Valenzano

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Amicus Therapeutics (United States)Purdue Pharma (United States)Purdue Pharma (Canada)Duke University Hospital Duke Medical Center

About

Kenneth J. Valenzano is an author at Amicus Therapeutics (United States) specializing in pharmacology, medicine, and molecular pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	20	1.6K
2	Biochemistry	9	9	431
3	Natural Sciences	7	7	375
4	Health Sciences	2	2	375
5	Social Sciences	2	2	510

Kenneth J. Valenzano

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Differential Regulation of the Dopamine D2and D3 Receptors by G Protein-coupled Receptor Kinases and β-Arrestins Kyeong‐Man Kim, Kenneth J. Valenzano, Susan R. Robinson, Journal of Biological Chemistry	2001	304
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy Kenneth J. Valenzano, Laykea Tafesse, Gary Lee, Neuropharmacology Cannabis UseMolecular PharmacologyPain ResearchHealth SciencesFunctional Selectivity	2005	282
Role of Dopamine Transporter in Methamphetamine-Induced Neurotoxicity: Evidence from Mice Lacking the Transporter Fabio Fumagalli, Raul R. Gainetdinov, Kenneth J. Valenzano, Journal of Neuroscience PsychopharmacologyMethamphetamine-induced NeurotoxicitySocial SciencesTotal Da ContentMolecular Pharmacology	1998	266
N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2 H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain James D. Pomonis, James Harrison, Lilly Mark, Journal of Pharmacology and Experimental Therapeutics	2003	260
N-(4-Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2 H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: I. In Vitro Characterization and Pharmacokinetic Properties Kenneth J. Valenzano, Elfrida R. Grant, Gang Wu, Journal of Pharmacology and Experimental Therapeutics	2003	249
Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice Fabio Fumagalli, Raul R. Gainetdinov, Yanmin Wang, Journal of Neuroscience Psychoactive DrugDopamine Transporter ExpressionNeurophysiologyAddictionMethamphetamine Neurotoxicity	1999	244
The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat Elfrida R. Benjamin, Maria Cecilia Della Valle, Xiaoyang Wu, Genetics in Medicine	2016	207
The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines John J. Flanagan, Adriane Schilling, Hui‐Hwa Chang, Journal of Inherited Metabolic Disease	2009	169
The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of <b>β</b>‐glucosidase Richie Khanna, Elfrida R. Benjamin, Lee Pellegrino, FEBS Journal	2010	158
The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease Richie Khanna, Rebecca Soska, Yi Lun, Molecular Therapy	2009	137

Page 1